Infective Endocarditis – Antibiotic Therapy Guidelines (Cited Evidence)

1. Native Valve Endocarditis – Viridans Streptococci & Streptococcus gallolyticus (bovis)

• Standard 4‑week β‑lactam regimen – For isolates with penicillin MIC ≤ 0.12 µg/mL, give Penicillin G 12–18 million U/day IV (divided 4–6 doses) or Ceftriaxone 2 g IV/IM once daily for 4 weeks. European Society of Cardiology recommendation. [1][2]
• Shortened 2‑week regimen with aminoglycoside – In uncomplicated cases with normal renal function, the same β‑lactam can be combined with Gentamicin 3 mg/kg/day IV/IM once daily for a total of 2 weeks. European Society of Cardiology recommendation. [1][2]
• Penicillin‑allergic patients – Use Vancomycin 30 mg/kg/day IV (divided) for 4 weeks, targeting trough 10–15 mg/L. European Society of Cardiology recommendation. [1][2]
• Relatively resistant strains (MIC 0.12–0.5 µg/mL) – Give Penicillin G 24 million U/day IV or Ceftriaxone 2 g/day IV for 4 weeks plus Gentamicin 3 mg/kg/day IV/IM for the first 2 weeks. European Society of Cardiology recommendation. [1][2]
• Penicillin‑allergic with reduced susceptibility – Vancomycin 30 mg/kg/day IV for 4 weeks plus Gentamicin 3 mg/kg/day for the first 2 weeks. European Society of Cardiology recommendation. [1][2]
• Highly resistant strains (MIC > 0.5 µg/mL) – Treat as enterococcal IE: Ampicillin or Penicillin plus Gentamicin for 4–6 weeks. European Society of Cardiology recommendation. [1][2]

2. Native Valve Endocarditis – Staphylococcus aureus

• Methicillin‑susceptible (MSSA) – Do not add Gentamicin to the β‑lactam regimen (Nafcillin/Oxacillin or Cefazolin). Infectious Diseases Society of America recommendation. [3][4]
• Methicillin‑resistant (MRSA) – Do not add Gentamicin or Rifampin to Vancomycin or Daptomycin therapy. Infectious Diseases Society of America recommendation. [3][4]
• Daptomycin dosing for MRSA IE – Standard dose 6 mg/kg IV daily; consider 8–10 mg/kg daily for complicated infections or when Vancomycin MIC > 1 µg/mL. Infectious Diseases Society of America recommendation. [3][4]

3. Native Valve Endocarditis – HACEK Organisms

• First‑line – Ceftriaxone 2 g IV/IM once daily for 4 weeks. American Heart Association recommendation. 5
• Alternative – Ampicillin‑Sulbactam 12 g IV daily (divided) for 4 weeks. American Heart Association recommendation. 5

4. Prosthetic Valve Endocarditis – Viridans Streptococci & S. gallolyticus

• Penicillin‑susceptible (MIC ≤ 0.12 µg/mL) – Penicillin G 24 million U/day IV or Ceftriaxone 2 g IV daily for 6 weeks, adding Gentamicin 3 mg/kg/day IV for the first 2 weeks. American Heart Association recommendation. 2
• Penicillin‑allergic – Vancomycin 30 mg/kg/day IV for 6 weeks plus Gentamicin 3 mg/kg/day for the first 2 weeks. American Heart Association recommendation. 2
• Reduced susceptibility (MIC > 0.12 µg/mL) – Same β‑lactam for 6 weeks plus Gentamicin for the full 6 weeks. American Heart Association recommendation. 2

5. Prosthetic Valve Endocarditis – HACEK Organisms

• Therapy – Ceftriaxone 2 g IV daily for 6 weeks. American Heart Association recommendation. 5

6. Therapeutic Drug Monitoring

• Gentamicin – Check serum levels weekly; target peak 3–4 µg/mL (or 10–12 mg/L for once‑daily dosing) and trough < 1 µg/mL. European Society of Cardiology recommendation. 1
• Vancomycin – Target trough 10–15 mg/L for streptococcal IE and 15–20 mg/L for staphylococcal IE. European Society of Cardiology recommendation. 1

Evidence strength: The cited guidelines do not specify explicit class/level designations in the extracted excerpts; therefore, the strength of evidence is not indicated.

Treatment of Infective Endocarditis

Introduction to Infective Endocarditis Treatment

• The American Heart Association recommends pathogen-specific antimicrobial therapy with beta-lactams as the cornerstone for most causative organisms, with specific regimens determined by the infecting organism and valve type (native vs. prosthetic) 6, 7

Staphylococcal Endocarditis

• For methicillin-susceptible Staphylococcus aureus (MSSA) native valve endocarditis, the American College of Cardiology recommends nafcillin or oxacillin 12 g/day IV in 6 divided doses for 4-6 weeks 7, 8
• For MSSA native valve endocarditis, cefazolin is an alternative for patients with non-immediate type hypersensitivity reactions to penicillin 7
• For methicillin-resistant S. aureus (MRSA) native valve endocarditis, the European Society of Cardiology recommends vancomycin 30-60 mg/kg/day IV in 2-3 divided doses for 4-6 weeks 9
• For MRSA with vancomycin MIC > 1 mg/L, daptomycin 10 mg/kg/day IV once daily is superior to vancomycin 9

Prosthetic Valve Endocarditis

• For MSSA prosthetic valve endocarditis, the American Heart Association recommends nafcillin or oxacillin 12 g/24h IV in 6 divided doses PLUS rifampin 900 mg/24h IV/PO in 3 divided doses for ≥6 weeks PLUS gentamicin 3 mg/kg/24h IV/IM in 2-3 divided doses for the first 2 weeks 6, 7
• For MRSA prosthetic valve endocarditis, vancomycin 30 mg/kg/24h in 2 divided doses PLUS rifampin 900 mg/24h IV/PO in 3 divided doses for ≥6 weeks PLUS gentamicin 3 mg/kg/24h IV/IM for the first 2 weeks is recommended 7

Enterococcal Endocarditis

• For penicillin-susceptible enterococci, the American College of Cardiology recommends ampicillin 2g IV every 4 hours (or penicillin G) PLUS gentamicin 3 mg/kg/day IV/IM in divided doses for 4-6 weeks 10, 11
• For aminoglycoside-resistant enterococci, double β-lactam therapy with ampicillin 2g IV every 4 hours PLUS ceftriaxone 2g IV every 12 hours for 6 weeks is recommended 12, 13

Important Clinical Considerations

• Bacteriological testing should always be performed to guide therapy, and organisms from surgical specimens or blood should be retested in case of relapse 7
• The duration of therapy is generally 4-6 weeks, with longer durations for prosthetic valve infections 6, 9
• Regular assessment of renal function is necessary, especially with aminoglycoside or vancomycin therapy 14
• Early surgical intervention should be considered for complications like heart failure, persistent bacteremia, or large vegetations 7

Common Pitfalls to Avoid

• Inadequate duration of therapy is associated with higher relapse rates 6, 7
• Monotherapy for enterococci is ineffective, and synergistic combinations are required 6
• Aminoglycoside use should be avoided in patients with creatinine clearance <50 mL/min or with high-level aminoglycoside resistance 11
• Delayed surgical intervention can be lifesaving in S. aureus PVE with complications 7
• Inappropriate beta-lactam use for MRSA can be ineffective despite in vitro susceptibility results 8